Sunshine Biopharma Inc (SBFM)

[StockRoomBully]

***Fda fast track. Covid Patent 3CLpro, nsp5 Treatment**_

The causative agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral 'polyproteins,' pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves the viral polyproteins' at a number of specific sites thereby generating a multi-subunit protein complex termed viral replicase-transcriptase'. Because of its functional indispensability in viral replication, Mpro is an attractive drug target for the development of a treatment for COVID-19 and other Coronavirus infections," said Dr. Slilaty.

"The kind of small molecules that we're developing are some of the first that are specifically designed for this coronavirus protease," Pegan said. "Up till now, most therapeutic work against SARS has targeted another virulence factor, C3Lpro. This is a great start with a different target. Our hope is that we can turn this into a starting point for creating a drug that we can get in front of the Food and Drug Administration."

"These compounds, naphthalene-based PLpro inhibitors, are shown to be effective at halting SARS-CoV-2 PLpro activity as well as replication. They offer a potential rapid development path to generating PLpro-targeted therapeutics for use against SARS-CoV-2."

https://www.streetinsider.com/dr/news.php?id=16966027&gfv=1

https://www.sciencedaily.com/releases/2020/06/200611133136.htm